1.The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, JC, Santos     More...

Fruchart, JC, Santos, RD, Aguilar-Salinas, C, Aikawa, M, Rasadi, K, Amarenco, P, Barter, PJ, Ceska, R, Corsini, A, Despres, JP, Duriez, P, Eckel, RH, Ezhov, MV, Farnier, M, Ginsberg, HN, Hermans, MP, Ishibashi, S, Karpe, F, Kodama, T, Koenig, W, Krempf, M, Lim, S, Lorenzatti, AJ, McPherson, R, Nunez-Cortes, JM, Nordestgaard, BG, Ogawa, H, Packard, CJ, Plutzky, J, Ponte-Negretti, CI, Pradhan, A, Ray, KK, Reiner, Z, Ridker, PM, Ruscica, M, Sadikot, S, Shimano, H, Sritara, P, Stock, JK, Su, TC, Susekov, AV, Tartar, A, Taskinen, MR, Tenenbaum, A, Tokgozoglu, LS, Tomlinson, B, Tybjaerg-Hansen, A, Valensi, P, Vrablik, M, Wahli, W, Watts, GF, Yamashita, S, Yokote, K, Zambon, A, Libby, P     Less

CARDIOVASCULAR DIABETOLOGY[1475-2840], Published 2019, Volume 18, Issue 1,

收錄情况： WOS SCOPUS

WOS核心合集引用: 92  2022影響因子:  9.3  发表年影響因子:  7.332